These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 28378879)

  • 1. Coxibs, Traditional NSAIDs, and Cardiovascular Safety Post-PRECISION: What We Thought We Knew Then and What We Think We Know Now.
    Patrono C; Baigent C
    Clin Pharmacol Ther; 2017 Aug; 102(2):238-245. PubMed ID: 28378879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs.
    Patrono C
    Curr Cardiol Rep; 2016 Mar; 18(3):25. PubMed ID: 26841787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
    Nissen SE; Yeomans ND; Solomon DH; Lüscher TF; Libby P; Husni ME; Graham DY; Borer JS; Wisniewski LM; Wolski KE; Wang Q; Menon V; Ruschitzka F; Gaffney M; Beckerman B; Berger MF; Bao W; Lincoff AM;
    N Engl J Med; 2016 Dec; 375(26):2519-29. PubMed ID: 27959716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs.
    Hermann M; Ruschitzka F
    Ann Med; 2007; 39(1):18-27. PubMed ID: 17364448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
    Solomon DH; Avorn J; Stürmer T; Glynn RJ; Mogun H; Schneeweiss S
    Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cardiovascular and gastrointestinal safety of NSAIDs].
    van den Bemt P; Tjwa ET; van Oijen MG
    Ned Tijdschr Geneeskd; 2014; 158():A7311. PubMed ID: 24713339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk.
    Moore RA; Derry S; McQuay HJ
    BMC Musculoskelet Disord; 2007 Aug; 8():73. PubMed ID: 17683540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coxibs Refocus Attention on the Cardiovascular Risks of Non-Aspirin NSAIDs.
    Thomas D; Ali Z; Zachariah S; Sundararaj KGS; Van Cuyk M; Cooper JC
    Am J Cardiovasc Drugs; 2017 Oct; 17(5):343-346. PubMed ID: 28353025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonsteroidal antiinflammatory drugs: past, present and future.
    Patrono C; Rocca B
    Pharmacol Res; 2009 May; 59(5):285-9. PubMed ID: 19416627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
    Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COX-2 selective inhibitors in the treatment of osteoarthritis.
    Laine L; White WB; Rostom A; Hochberg M
    Semin Arthritis Rheum; 2008 Dec; 38(3):165-87. PubMed ID: 18177922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis.
    Gunter BR; Butler KA; Wallace RL; Smith SM; Harirforoosh S
    J Clin Pharm Ther; 2017 Feb; 42(1):27-38. PubMed ID: 28019014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonsteroidal anti-inflammatory drugs and cardiovascular safety - translating pharmacological data into clinical readouts.
    Tacconelli S; Bruno A; Grande R; Ballerini P; Patrignani P
    Expert Opin Drug Saf; 2017 Jul; 16(7):791-807. PubMed ID: 28569569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular effects of coxibs.
    Caporali R; Montecucco C
    Lupus; 2005; 14(9):785-8. PubMed ID: 16218488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The murky waters of the coxibs: a review of the current state of play.
    Ostor AJ; Hazleman BL
    Inflammopharmacology; 2005; 13(4):371-80. PubMed ID: 16354390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclooxygenase-2 inhibitors: what went wrong?
    James MJ; Cleland LG
    Curr Opin Clin Nutr Metab Care; 2006 Mar; 9(2):89-94. PubMed ID: 16477171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclooxygenase-2 inhibitors, nonsteroidal anti-inflammatory drugs, and cardiovascular risk.
    Vardeny O; Solomon SD
    Cardiol Clin; 2008 Nov; 26(4):589-601. PubMed ID: 18929233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen.
    De Vecchis R; Baldi C; Di Biase G; Ariano C; Cioppa C; Giasi A; Valente L; Cantatrione S
    Minerva Cardioangiol; 2014 Dec; 62(6):437-48. PubMed ID: 25029569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
    Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
    J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.
    Matchaba P; Gitton X; Krammer G; Ehrsam E; Sloan VS; Olson M; Mellein B; Hoexter G; Orloff J; Garaud JJ
    Clin Ther; 2005 Aug; 27(8):1196-214. PubMed ID: 16199245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.